



VGX Pharmaceuticals provides clinical trials and product development updates

Blue Bell, PA – October 17, 2007 –

VGX Pharmaceuticals has provided the following updates on the Company's clinical trials and product development progress:

PICTOVIR™: The Company has completed dosing of patients in 2 dose groups (300 mg and 600 mg per day) in a multi-site, multi-dose, and double-blind Phase II study and has filed a safety report with the FDA summarizing the tolerability of these doses. VGX is currently working through the FDA requirements for conducting clinical studies for using PICTOVIR™ in combination with other front-line treatments without the need to progress to a 1200 mg dose. All current HIV drug regimens use a combination of 3 or 4 drugs to increase efficacy and to reduce the virus' development of resistance to the drugs.

VGX-410C: VGX has completed the dosing of the last patient in this multi-site, multi-dose, and double-blind Phase II study for assessing the drug's safety and antiviral effects and is conducting follow-up analyses per the clinical protocol. The Company is on schedule for the unblinding and announcing of all clinical data by the end of 2007.

VGX-1027: VGX has completed IND-enabling pre-clinical toxicology studies for VGX-1027 (Type 1 Diabetes and Rheumatoid Arthritis) and cGMP manufacturing of clinical-grade products. The Company expects to file an Investigational New Drug Application (IND) with the FDA in December 2007.

CELLECTRA™: VGX's patented electroporation device has been validated for human use. VGX is developing the CELLECTRA™ electroporation device to deliver a number of DNA vaccine and therapeutic candidates. This unique technology optimizes DNA uptake and subsequent expression by adapting an applied electric field strength in real-time to sense the tissue micro-environment. The device is portable, water-proof, shock-proof, battery operated, and software driven, making it particularly suited for usage in the field. The Company will initiate and complete its first study for tolerability of this device in human volunteers by the end of 2007.

DNA Vaccines (Syringe Delivery): VGX's most advanced DNA vaccines product is PENNVAX-B™, which focuses on the prevention and treatment of HIV infection. The Company will initiate 2 separate Phase I clinical trials in 2007; one for prophylactic vaccination and the other for therapeutic vaccination. Both trials will be conducted in clinical centers in the U.S. in collaboration with the University of Pennsylvania and the HIV Vaccines Trials Network (HVTN), which is the largest HIV vaccine testing organization in the world and funded by the U.S. National Institutes of Health (NIH). VGX is planning additional Phase I clinical studies for PENNVAX-B™, delivered with CELLECTRA™, in collaboration with the HVTN for 2008.

DNA Vaccines (CELLECTRA™ Delivery): VGX has initiated IND-enabling pre-clinical toxicology studies for three of its DNA plasmid-based product candidates delivered by CELLECTRA™ electroporation device. The candidates include vaccines for human papilloma virus as a treatment for cervical cancer (VGX-3100) and avian influenza (VGX-3400), and a therapeutic based on human growth hormone releasing hormone (VGX-3200) for cancer-related cachexia. The Company expects to complete the toxicology studies in early 2008, and to file the INDs for all three products by June 2008.

VGX Animal Health Products: VGX has initiated IND-enabling pre-clinical toxicology studies for three of its DNA plasmid-based product candidates delivered by CELLECTRA™ electroporation device. The candidates include vaccines for human papilloma virus as a treatment for cervical cancer (VGX-3100) and avian influenza (VGX-3400), and a therapeutic based on human growth hormone releasing hormone (VGX-3200) for cancer-related cachexia. The Company expects to complete the toxicology studies in early 2008, and to file the INDs for all three products by June 2008.

Cautionary Factors That May Affect Future Results - Materials in this Press Release contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of VGX stock. It is also important to read the disclosure notice contained in many of the individual VGX documents available on www.vgxp.com as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.

About VGX Pharmaceuticals

VGX Pharmaceuticals is a biopharmaceutical company with small molecule and biologic product candidates for the treatment of infectious diseases, cancer, and inflammatory diseases. The Company's clinical development programs include PICTOVIR™ for HIV infection, which is in Phase II clinical trials, and PENNVAX™-B, a DNA vaccine for preventing HIV infection, which is in Phase I clinical trials. In addition, VGX is planning to initiate Phase I clinical studies for VGX-1027, its lead compound for inflammatory diseases. VGX's research pipeline includes a new generation of SynCon™ DNA vaccines and therapeutics as well as the CELLECTRA™ electroporator, a patented DNA delivery device. The product candidates and technology programs are protected by the Company's extensive global intellectual property portfolio. More information about VGX can be found at www.vgxp.com.

Company Contact:

Kevin W. Rassas
Senior Vice President
Tel. 267.440.4208
Fax 267.440.4242
E-mail: Rassas@vgxp.com
www.vgxp.com